EBITDA fell to NOK 554 million in Q3 2026 as weak silicon prices hit results; foundry alloys and carbon outperformed and new EU trade measures and allowances improve the outlook.
Long-term electricity secured for an Iceland ferrosilicon plant: 127 MW PPA with flexible pricing from April 2029 that ties partly to the ferrosilicon market while keeping a price floor.
EU clears first PD‑1 inhibitor plus ADC regimen for resectable muscle‑invasive bladder cancer regardless of cisplatin eligibility; phase 3 showed EFS HR 0.53 and OS HR 0.65.
CHMP recommends approval after KEYNOTE-B15 showed event-free survival, overall survival and pathologic complete response gains; European Commission decision expected Q4 2026.
Phase 3b data indicate a single Bexsero booster at age 10+ boosts immunity in those primed in infancy; full study results will be presented at IPNC in September.
EBITDA fell on weak silicon prices; raised NOK 1.8bn, refinanced EUR 1bn facility and obtained NOK 750m NIB loan; Elkem Iceland reclassified as discontinued.
EU selects fourth common auction platform for its emissions trading system; auctions begin 2027 and ETS2 auctioning starts January 2027 while ETS2 operations start in 2028.
Feasibility and financial modelling launched for a Kuopio flagship plant that aims to scale electro-based sustainable aviation fuel across the Nordics by 2040.
CHMP backed perioperative regimen for cisplatin‑ineligible resectable MIBC after Phase 3 KEYNOTE‑905 showed significant EFS, OS and pCR gains; EC decision due by Q3 2026; FDA cleared Nov 2025.
EBITDA fell 2.9% to €13.0m while sales dropped 12% to €221.0m; EBT improved on exchange-rate effects; Trading & Services and logistics strengthened; bond repaid €21.0m.
active / all projects
